Trinity Biotech plc

Equities

TRIB

US8964385046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 14/06/2024 BST			5-day change	1st Jan Change
2.78 ^USD	-19.65%		+32.38%	+29.60%

06-14	European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	MT
06-13	European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading	MT

Trinity Biotech plc Reports Earnings Results for the First Quarter Ended March 31, 2024

May 23, 2024 at 01:00 pm

Trinity Biotech plc reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 14.7 million compared to USD 14.83 million a year ago. Net loss was USD 3.32 million compared to USD 5.81 million a year ago.

Latest news about Trinity Biotech plc

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	06-14	MT
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading	06-13	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	06-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	06-11	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	06-05	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	06-04	MT
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	06-03	MT
Trinity Biotech plc Launches Its Continuous Glucose Monitoring Microsite to Showcase Its Innovative & Differentiated Technology	06-03	CI
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	05-31	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	05-30	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	05-29	MT
Transcript : Trinity Biotech plc, Q1 2024 Earnings Call, May 23, 2024	05-23
Trinity Biotech plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	05-22	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	05-21	MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading	05-20	MT
Trinity Biotech plc Receives Substantial Additional Orders for TrinScreen HIV	05-16	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	05-16	MT
Trinity Biotech Announces Strategic Collaboration with PulseAI	05-16	CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	05-14	MT
Trinity Biotech Secures Additional Orders For TrinScreen HIV Rapid Test Product	05-13	MT
Trinity Biotech plc Revises Revenue Guidance for the Fourth Quarter of 2024	05-13	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	05-10	MT
Trinity Biotech Announces the Appointment of Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development	05-08	CI
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	05-07	MT

Chart Trinity Biotech plc

Duration

Period

More charts

Company Profile

Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
TRINITY BIOTECH PLC	+29.60%	26.31M
BIOMÉRIEUX	-9.74%	11.48B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.80%	7.64B
LANTHEUS HOLDINGS, INC.	+27.84%	5.49B
AUTOBIO DIAGNOSTICS CO., LTD.	-15.47%	3.86B
ANDON HEALTH CO., LTD.	+8.47%	2.61B
10X GENOMICS, INC.	-63.81%	2.42B
VITROLIFE AB	-9.24%	2.27B
MYRIAD GENETICS, INC.	+21.21%	2.1B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-9.38%	1.76B

Diagnostic & Testing Substances